Cargando…

Safety, Pharmacokinetics, and Pharmacodynamics of CC‐90001 (BMS‐986360), a c‐Jun N‐terminal Kinase Inhibitor, in Phase 1 Studies in Healthy Participants

CC‐90001 selectively inhibits c‐Jun N‐terminal kinase (JNK), a stress‐activated protein implicated in fibrosis. In 3 phase 1 trials evaluating CC‐90001 pharmacokinetics, pharmacodynamics, and safety, healthy adults (N = 184) received oral CC‐90001 in a single dose (10–720 mg) or multiple doses (30–4...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ye, Ying, Gaudy, Allison, Thomas, Michael, Reyes, Josephine, Burkhardt, Barbara, Horan, Gerald, Liu, Liangang, Chen, Jian, Ghosh, Atalanta, Carayannopoulos, Leonidas N., Tatosian, Daniel A., Palmisano, Maria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092235/ https://www.ncbi.nlm.nih.gov/pubmed/36256505 http://dx.doi.org/10.1002/cpdd.1178

Ejemplares similares

CC-90001, a c-Jun N-terminal kinase (JNK) inhibitor, in patients with pulmonary fibrosis: design of a phase 2, randomised, placebo-controlled trial
por: Popmihajlov, Zoran, et al.
Publicado: (2022)

First‐in‐Human, Single‐ and Multiple‐Ascending‐Dose Studies in Healthy Subjects to Assess Pharmacokinetics, Pharmacodynamics, and Safety/Tolerability of Iberdomide, a Novel Cereblon E3 Ligase Modulator
por: Ye, Ying, et al.
Publicado: (2020)

Drug‐Drug Interaction Study to Assess the Effect of Cytochrome P450 Inhibition and Induction on the Pharmacokinetics of the Novel Cereblon Modulator Avadomide (CC‐122) in Healthy Adult Subjects
por: Ogasawara, Ken, et al.
Publicado: (2019)

Model based assessment of food and acid reducing agent effects on oral absorption of mezigdomide (CC‐92480), a novel cereblon E3 ligase modulator
por: Wu, Fan, et al.
Publicado: (2023)

Exposure-response analysis to assess the concentration–QTc relationship of CC-122
por: Li, Yan, et al.
Publicado: (2016)

Safety, pharmacokinetics, and pharmacodynamics of BMS-986142, a novel reversible BTK inhibitor, in healthy participants
por: Lee, Sun Ku, et al.
Publicado: (2017)

Multiple-Dose Pharmacokinetics of Ozanimod and its Major Active Metabolites and the Pharmacodynamic and Pharmacokinetic Interactions with Pseudoephedrine, a Sympathomimetic Agent, in Healthy Subjects
por: Tran, Jonathan Q., et al.
Publicado: (2020)

Dapagliflozin: BMS 512148; BMS-512148
Publicado: (2012)

P825: SOLUBLE FACTORS CORRELATED WITH CYTOKINE RELEASE SYNDROME (CRS) WITH IV VS SUBCUTANEOUS (SC) ALNUCTAMAB (ALNUC; BMS-986349; CC-93269) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
por: Boss, Isaac, et al.
Publicado: (2023)

Effect of fluconazole on the pharmacokinetics of a single dose of fedratinib in healthy adults
por: Chen, Yizhe, et al.
Publicado: (2022)

Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies
por: Laille, Eric, et al.
Publicado: (2015)

Combination of GT90001 and nivolumab in patients with advanced hepatocellular carcinoma: a multicenter, single-arm, phase 1b/2 study
por: Hsu, Chiun, et al.
Publicado: (2023)

Clinical Pharmacokinetics and Pharmacodynamics of Lenalidomide
por: Chen, Nianhang, et al.
Publicado: (2016)

Crystal structures of trimeric HIV Env with entry inhibitors BMS-378806 and BMS-626529
por: Pancera, Marie, et al.
Publicado: (2017)

Barrel-muon-spectrometer: BMS
Publicado: (2005)

Barrel-muon-spectrometer: BMS
Publicado: (2005)

Barrel-muon-spectrometer: BMS
Publicado: (2005)

Barrel-muon-spectrometer: BMS
Publicado: (2005)

Barrel-muon-spectrometer: BMS
Publicado: (2005)

Barrel-muon-spectrometer: BMS
Publicado: (2005)

Barrel-muon-spectrometer: BMS
Publicado: (2005)

A Phase 1, Multicenter, Open-Label Study to Evaluate the Pharmacokinetics of Iberdomide in Subjects with Mild, Moderate, or Severe Hepatic Impairment Compared with Healthy Subjects
por: Cheng, Yiming, et al.
Publicado: (2023)

Single and multiple dose pharmacokinetics and pharmacodynamics of omarigliptin, a novel, once‐weekly dipeptidyl peptidase‐4 inhibitor, in healthy Japanese men
por: Tsuchiya, Saori, et al.
Publicado: (2016)

Construction of the MPI BMS Prototype Chamber
por: Bratzler, U, et al.
Publicado: (1997)

Safety, pharmacokinetics and pharmacodynamics of branebrutinib (BMS‐986195), a covalent, irreversible inhibitor of Bruton's tyrosine kinase: Randomised phase I, placebo‐controlled trial in healthy participants
por: Catlett, Ian M., et al.
Publicado: (2020)

An Open‐Label, Phase 1 Study to Assess the Effects of Hepatic Impairment on Pomalidomide Pharmacokinetics
por: Li, Yan, et al.
Publicado: (2018)

First‐in‐human study to assess the safety, pharmacokinetics and pharmacodynamics of BMS‐962212, a direct, reversible, small molecule factor XIa inhibitor in non‐Japanese and Japanese healthy subjects
por: Perera, Vidya, et al.
Publicado: (2018)

c-Jun N-terminal kinase 2 suppresses pancreatic cancer growth and invasion and is opposed by c-Jun N-terminal kinase 1
por: Tian, Xiaodong, et al.
Publicado: (2021)

BMS1 Is Mutated in Aplasia Cutis Congenita
por: Marneros, Alexander G.
Publicado: (2013)

In Vivo Assessment of the Effect of CYP1A2 Inhibition and Induction on Pomalidomide Pharmacokinetics in Healthy Subjects
por: Li, Yan, et al.
Publicado: (2018)

Pharmacodynamic activity of BMS-986156, a glucocorticoid-induced TNF receptor-related protein agonist, alone or in combination with nivolumab in patients with advanced solid tumors
por: Wang, R., et al.
Publicado: (2023)

Population Pharmacokinetics of Pomalidomide
por: Li, Yan, et al.
Publicado: (2015)

c-Jun N-Terminal Kinase in Inflammation and Rheumatic Diseases
por: Guma, Monica, et al.
Publicado: (2012)

Jun N-terminal kinase signaling makes a face
por: Hursh, Deborah A., et al.
Publicado: (2016)

Distribution of pomalidomide into semen of healthy male subjects after multiple doses
por: Li, Yan, et al.
Publicado: (2018)

P883: ALNUCTAMAB (ALNUC; BMS-986349; CC-93269), A BCMA × CD3 T-CELL ENGAGER, IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): LATEST RESULTS FROM A PHASE 1 FIRST-IN-HUMAN CLINICAL STUDY
por: Wong, Sandy W., et al.
Publicado: (2023)

Role of Mitochondrial Toxicity in BMS-986094-Induced Toxicity
por: Feng, Joy Y., et al.
Publicado: (2017)

Effect of BMS-470539 on lipopolysaccharide-induced neutrophil activation
por: Lee, Seongheon, et al.
Publicado: (2020)

Krox-20 inhibits Jun-NH(2)-terminal kinase/c-Jun to control Schwann cell proliferation and death
por: Parkinson, David B., et al.
Publicado: (2004)

C‐Jun N‐terminal kinase signalling pathway in response to cisplatin
por: Yan, Dong, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_4djs1vqg568l9au56dtrmqmfpv